IHL 0.00% 4.1¢ incannex healthcare limited

General discussion, page-19487

  1. 3,848 Posts.
    lightbulb Created with Sketch. 1920
    - income derived from Clarion (some numbers)............... Not until the first qtyly after patents have begin therapy. This could be 2nd quarter.
    - a cap raise........................................Not at this level of liquidity. I would assume a major push in developments leading into a raising.

    Next lot of news

    Near term;
    *Updated and the RePosa TP2B3 site approvals and accepting patents.
    *Analytic report and TP2 PSIGAD
    *Pre IND/FDA feed back on PSIGAD TP2B for the US
    *Updates on CannQuit N trials
    *Mr Robert Clark's package updates. Assume that this package will be re-negotiated.

    *Possibly;
    675A interim data. Early H2
    Regulatory developments in Europe for the RePosa trials.
    Regulatory developments in UK for PSIGAD trials.
    CannQuit O. Bigger TAM than CannQuit N. (Having 4 trials might be a tall order with available COH)
    Clarion updates and Qtrly. Late H2

    Hopefully;
    Once Analytic PSIGAD report, patent intake with Reposa TP2B3, CannQuit N updates and positive PSI TP2B FDA feedback a new and updated presentation squarely focused on the US market focusing on late stage drug developments and benchmarks. Commencing RePosa TP2B3 will be a huge milestone for Incannex bring IHL-42X our first drug/compound asset squarely into late stage development. A big tick for the US investors.

    GL @Slyau90

 
watchlist Created with Sketch. Add IHL (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.